AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17580725 — intervention group
Group type: COMPARATOR
Intervention: Unaided performance
Number of subjects: 108
Study 17580725 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid benefit
Number of subjects: 108
Study 17580725 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech-recognition performance on NU-6 and CST tests
Number of subjects: 108
Study 15866314 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11919117 — intervention group
Group type: EXPERIMENTAL
Intervention: DPL (dermal Powderject lidocaine) at 40 bar with small particles
Number of subjects: 132
Study 11919117 — intervention group
Group type: EXPERIMENTAL
Intervention: DPL (dermal Powderject lidocaine) at 40 bar with large particles
Number of subjects: 132
Study 11919117 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 132
Study 10354658 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg per day)
Number of subjects: 173
Study 10354658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 8923916 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography for evaluating endometrial grades and hormone levels (progesterone and estradiol).
Number of subjects: 0
Study 2025473 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperbaric 0.5% bupivacaine 2.5 ml at L2-3 (n = 20)
Number of subjects: 40
Study 2025473 — intervention group
Group type: COMPARATOR
Intervention: hyperbaric 0.5% bupivacaine 2.5 ml at L4-5 (n = 20)
Number of subjects: 40
Study 7044682 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin prophylaxis (5000 U subcutaneously twice daily)
Number of subjects: 119
Study 7044682 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 119
Study 7044682 — intervention group
Group type: COMPARATOR
Intervention: Untreated medical patients
Number of subjects: 119
Study 7044682 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated medical patients
Number of subjects: 119
Study 31593528 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback device
Number of subjects: 24
Study 31593528 — intervention group
Group type: COMPARATOR
Intervention: Without real-time feedback device
Number of subjects: 24
Study 30115082 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of creativity (C+)
Number of subjects: 16
Study 30115082 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditions promoting creativity (C+ with or without visual display)
Number of subjects: 16
Study 30115082 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of creativity and omission of visual display
Number of subjects: 16
Study 30115082 — intervention group
Group type: COMPARATOR
Intervention: All four training conditions
Number of subjects: 16
Study 27367743 — intervention group
Group type: EXPERIMENTAL
Intervention: BBFC+PGA
Number of subjects: 0
Study 27367743 — intervention group
Group type: COMPARATOR
Intervention: Vehicle+PGA
Number of subjects: 0
Study 24429845 — intervention group
Group type: EXPERIMENTAL
Intervention: Secoisolariciresinol-diglycoside (SDG) at doses of 25, 50, 75, 86, and 172 mg
Number of subjects: 0
Study 24429845 — intervention group
Group type: EXPERIMENTAL
Intervention: Secoisolariciresinol-diglycoside (SDG)
Number of subjects: 0
Study 22431963 — intervention group
Group type: EXPERIMENTAL
Intervention: Rintatolimod (Poly I: C(12)U) 400 mg twice weekly
Number of subjects: 234
Study 22431963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 20549835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of asenapine (5 mg)
Number of subjects: 36
Study 20549835 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal administration of asenapine (5 mg)
Number of subjects: 36
Study 20549835 — intervention group
Group type: EXPERIMENTAL
Intervention: Supralingual administration of asenapine (5 mg)
Number of subjects: 36
Study 18257188 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint-injection therapy with Jingming (BL 1), Yangbai (GB 14), Sibai (ST 2), Tongziliao (GB 1), bilateral Ganshu (BL 18), and compound Danggui Injection as the principal injected medicine.
Number of subjects: 76
Study 18257188 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine therapy.
Number of subjects: 76
Study 18257188 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint-injection therapy
Number of subjects: 76
Study 18257188 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine therapy
Number of subjects: 76
Study 16498927 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic (120 ml at 2.5 ml/s)
Number of subjects: 60
Study 16498927 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-high biphasic (120 ml, first 60 ml at 2 ml/s, the other 60 ml at 2.5 ml/s)
Number of subjects: 60
Study 16498927 — intervention group
Group type: EXPERIMENTAL
Intervention: High-low biphasic (120 ml, first 60 ml at 2.5 ml/s, the other 60 ml at 2 ml/s)
Number of subjects: 60
Study 12735667 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing retraining
Number of subjects: 0
Study 12735667 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10907802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (48 mg/day, range 10 mg to 60 mg)
Number of subjects: 12
Study 10907802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8887059 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) administered both topically and intramuscularly for 15 days
Number of subjects: 3
Study 1712273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 1.25 to 5 mg daily
Number of subjects: 33
Study 1712273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 1712273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (single dose of 2.5 or 5 mg)
Number of subjects: 33
Study 6761849 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 28
Study 6761849 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 28
Study 30738426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol high-dose (1050 mg/day)
Number of subjects: 75
Study 30738426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol low-dose (525 mg/day)
Number of subjects: 75
Study 30738426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 30738426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (both doses)
Number of subjects: 75
Study 28775306 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine with four doses
Number of subjects: 1544
Study 28775306 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine with three doses
Number of subjects: 1544
Study 28775306 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1544
Study 25974251 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 in anti-TNF naïve Crohn's disease patients
Number of subjects: 74
Study 25974251 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 in anti-TNF naïve ulcerative colitis patients
Number of subjects: 74
Study 25974251 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 after switching from originator in Crohn's disease patients
Number of subjects: 74
Study 25974251 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 after switching from originator in ulcerative colitis patients
Number of subjects: 74
Study 25974251 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 in ulcerative colitis patients
Number of subjects: 74
Study 23809312 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Tailored Exercise Program (MSTEP)
Number of subjects: 240
Study 23809312 — intervention group
Group type: COMPARATOR
Intervention: General guidelines for exercise
Number of subjects: 240
Study 21076273 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 recombinant canarypox vaccine (vCP1452)
Number of subjects: 65
Study 21076273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 19772786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular neridronate (NE) 25 mg monthly
Number of subjects: 69
Study 17722830 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Futu (LI 18), Renying (ST 9), Shuitu (ST 10) and cake-separated moxibustion at Yongquan (KI 1)
Number of subjects: 90
Study 17722830 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Huang's Xiang Sheng Pills
Number of subjects: 90
Study 17722830 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus moxibustion
Number of subjects: 90
Study 15593057 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 9
Study 15593057 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 9
Study 11423717 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 16
Study 11423717 — intervention group
Group type: COMPARATOR
Intervention: Exercise stress test
Number of subjects: 16
Study 8072255 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (5 mg/kg body weight) administered intravenously 45 minutes before CM application.
Number of subjects: 39
Study 8072255 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) administered intravenously 45 minutes before CM application.
Number of subjects: 39
Study 3134810 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg)
Number of subjects: 40
Study 3134810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31650662 — intervention group
Group type: COMPARATOR
Intervention: individual internet-based Mindfulness-Based Cognitive Therapy (eMBCT)
Number of subjects: 245
Study 31650662 — intervention group
Group type: COMPARATOR
Intervention: group-based face-to-face Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 245
Study 31650662 — intervention group
Group type: EXPERIMENTAL
Intervention: treatment as usual (TAU)
Number of subjects: 245
Study 31412947 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oropharyngeal exercises (respiratory muscle training, 3 times/day, 5 days/week, for 21 weeks)
Number of subjects: 52
Study 31412947 — intervention group
Group type: COMPARATOR
Intervention: Standard swallow therapy (control group)
Number of subjects: 52
Study 28587977 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight implants (S, n=37)
Number of subjects: 21
Study 28587977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilted implants (T, n=33)
Number of subjects: 21
Study 25705800 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of hydrocortisone (0.2-0.3 mg/kg body weight/day) for 10 weeks
Number of subjects: 47
Study 25705800 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of hydrocortisone (0.4-0.6 mg/kg body weight/day) for 10 weeks
Number of subjects: 47
Study 25705800 — intervention group
Group type: COMPARATOR
Intervention: High dose of hydrocortisone
Number of subjects: 47
Study 23826093 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2 mg nicotine cartridges for 12 weeks (Group A)
Number of subjects: 300
Study 23826093 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week 7.2 mg nicotine cartridges followed by 6-week 5.4 mg nicotine cartridges (Group B)
Number of subjects: 300
Study 23826093 — intervention group
Group type: COMPARATOR
Intervention: No-nicotine cartridges for 12 weeks (Group C)
Number of subjects: 300
Study 21950148 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg felodipine (Plendil)
Number of subjects: 100
Study 21950148 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg felodipine (Plendil)
Number of subjects: 100
Study 19702377 — intervention group
Group type: EXPERIMENTAL
Intervention: Employee testimonials included on recruitment websites
Number of subjects: 0
Study 19702377 — intervention group
Group type: EXPERIMENTAL
Intervention: Video with audio testimonials
Number of subjects: 0
Study 19702377 — intervention group
Group type: COMPARATOR
Intervention: Picture with text testimonials
Number of subjects: 0
Study 19702377 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of minorities shown in testimonials
Number of subjects: 0
Study 19702377 — intervention group
Group type: EXPERIMENTAL
Intervention: Richer medium (video with audio)
Number of subjects: 0
Study 16882618 — intervention group
Group type: EXPERIMENTAL
Intervention: GSM RadioFrequency (RF) exposure
Number of subjects: 15
Study 15028546 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training (PT)
Number of subjects: 159
Study 15028546 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent plus teacher training (PT + TT)
Number of subjects: 159
Study 15028546 — intervention group
Group type: EXPERIMENTAL
Intervention: Child training (CT)
Number of subjects: 159
Study 15028546 — intervention group
Group type: EXPERIMENTAL
Intervention: Child plus teacher training (CT + TT)
Number of subjects: 159
Study 15028546 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent, child, plus teacher training (PT + CT + TT)
Number of subjects: 159
Study 15028546 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 159
Study 11555501 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin therapy
Number of subjects: 109
Study 11555501 — intervention group
Group type: COMPARATOR
Intervention: Control (no active treatment)
Number of subjects: 109
Study 9802627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 93
Study 9802627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 9802627 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple acute pneumonia episodes
Number of subjects: 93
Study 9802627 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HIV RNA copy number and CD4+ percentage
Number of subjects: 93
Study 8151000 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (4 or 8 mg/day, sublingual)
Number of subjects: 26
Study 3276009 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (n = 10)
Number of subjects: 20
Study 3276009 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide (n = 10)
Number of subjects: 20
Study 29993218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic lidocaine and dexamethasone (ITLD)
Number of subjects: 44
Study 29993218 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic dexamethasone (ITD)
Number of subjects: 44
Study 29206824 — intervention group
Group type: EXPERIMENTAL
Intervention: One-shot procedure
Number of subjects: 59
Study 29206824 — intervention group
Group type: COMPARATOR
Intervention: Sequential dilatation
Number of subjects: 59
Study 26136585 — intervention group
Group type: EXPERIMENTAL
Intervention: High-polyphenol-content olive oil (HPCOO; 2.7 mg/kg)
Number of subjects: 25
Study 26136585 — intervention group
Group type: COMPARATOR
Intervention: Low-polyphenol-content olive oil (LPCOO; 366 mg/kg)
Number of subjects: 25
Study 24140874 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement approach
Number of subjects: 124
Study 24140874 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 124
Study 20577097 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Contour Tonometry (DCT)
Number of subjects: 116
Study 20577097 — intervention group
Group type: COMPARATOR
Intervention: Goldmann Applanation Tonometry (GAT)
Number of subjects: 116
Study 20577097 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Corneal Thickness (CCT)
Number of subjects: 116
Study 18303125 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept (single subcutaneous or repeated every other week dose)
Number of subjects: 0
Study 18303125 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 16977263 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII) with insulin lispro (n=20)
Number of subjects: 33
Study 16977263 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Insulin Infusion (IVII) with regular insulin (n=13)
Number of subjects: 33
Study 16977263 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CSII and IVII
Number of subjects: 33
Study 16977263 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Insulin Infusion (IVII)
Number of subjects: 33
Study 16977263 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII)
Number of subjects: 33
Study 14676996 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral radiofrequency energy (RFe) tissue micro‐remodeling
Number of subjects: 41
Study 12362961 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure (VRE)
Number of subjects: 45
Study 12362961 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo group treatment (GT)
Number of subjects: 45
Study 9746961 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (58-65 Gy) with razoxane as radiosensitizer in 4 patients
Number of subjects: 10
Study 9746961 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with clear margins (R-0 resection) in 5 patients, microscopic residuals (R-1) in 3, and gross residual disease in 1 patient
Number of subjects: 10
Study 9746961 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vindesine, razoxane, and radiotherapy in 1 patient
Number of subjects: 10
Study 7971878 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus efficacy-based intervention
Number of subjects: 114
Study 7971878 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus attentional control
Number of subjects: 114
Study 2532681 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinse volumes of 2 ml, 5 ml, 10 ml, 15 ml, or 25 ml with air and water syringe pressures of 20/10, 20/40, 40/10, or 40/40 psi.
Number of subjects: 384
Study 2532681 — intervention group
Group type: COMPARATOR
Intervention: 0 ml rinse volume with air and water syringe pressures of 20/10, 20/40, 40/10, or 40/40 psi.
Number of subjects: 384
Study 132988 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture (needles placed into acupuncture points for low back pain)
Number of subjects: 30
Study 132988 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (needles randomly placed in areas not related to low back pain)
Number of subjects: 30
Study 31517791 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Chronic Care Model (CCM) implemented in outpatient mental health teams from 2015 to 2018 across 9 sites.
Number of subjects: 0
Study 31517791 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence synthesis and systematic review of randomized controlled trials of CCMs for mental health conditions.
Number of subjects: 0
Study 31517791 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of 17 facilitators and engagement of 28 facilities in the CCM scale-up effort in 2017.
Number of subjects: 0
Study 28955416 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5mg once daily for 4 weeks)
Number of subjects: 50
Study 28955416 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25mg once daily for 4 weeks)
Number of subjects: 50
Study 25841237 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium (GLY) 50 µg once daily + Salmeterol/Fluticasone (SAL/FP) 50/500 µg twice daily
Number of subjects: 773
Study 25841237 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 µg once daily + Salmeterol/Fluticasone (SAL/FP) 50/500 µg twice daily
Number of subjects: 773
Study 25841237 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) + Salmeterol/Fluticasone (SAL/FP) 50/500 µg twice daily
Number of subjects: 773
Study 24225138 — intervention group
Group type: EXPERIMENTAL
Intervention: Caseload midwifery
Number of subjects: 10
Study 24225138 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 10
Study 21629270 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml camel milk in addition to usual care (diet, exercise, and insulin)
Number of subjects: 24
Study 21629270 — intervention group
Group type: COMPARATOR
Intervention: Usual care (diet, exercise, and insulin)
Number of subjects: 24
Study 18073318 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondhand smoke (SHS) exposure for 1 hour
Number of subjects: 28
Study 18073318 — intervention group
Group type: COMPARATOR
Intervention: Control trial (no SHS exposure)
Number of subjects: 28
Study 16429457 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha tocopherol (AT) supplementation (134 or 268 mg/day)
Number of subjects: 32
Study 12943173 — intervention group
Group type: EXPERIMENTAL
Intervention: Hachimi‐jio‐gan (HJG)
Number of subjects: 12
Study 12943173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10845009 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 CGE (Cobalt Gray Equivalent)
Number of subjects: 46
Study 10845009 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 CGE (Cobalt Gray Equivalent)
Number of subjects: 46
Study 9357241 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg aspirin daily from day of positive ROT till 37 weeks of pregnancy
Number of subjects: 50
Study 9357241 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 50
Study 8187656 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 73
Study 8187656 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine/sulphadoxine (P/SD)
Number of subjects: 73
Study 8187656 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine/sulfalene (P/SL)
Number of subjects: 73
Study 8187656 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 73
Study 31211612 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus aurantium aroma (neroli oil) inhalation, 30% essential oil in paraffin, administered three times a day
Number of subjects: 140
Study 31211612 — intervention group
Group type: COMPARATOR
Intervention: Placebo (paraffin)
Number of subjects: 140
Study 29674483 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-cell stents
Number of subjects: 1557
Study 29674483 — intervention group
Group type: COMPARATOR
Intervention: Closed-cell stents
Number of subjects: 1557
Study 29674483 — intervention group
Group type: EXPERIMENTAL
Intervention: Protection devices (predominantly distal filters)
Number of subjects: 1557
Study 29674483 — intervention group
Group type: COMPARATOR
Intervention: No protection devices
Number of subjects: 1557